Evidence map›Paper›PMID 31812978›Full record

ArticleMedical science monitor : international medical journal of experimental and clinical research2019

Spleen Tyrosine Kinase (SYK) in the Progression of Peritoneal Fibrosis Through Activation of the TGF-β1/Smad3 Signaling Pathway.

Kang-Han Liu, Nan Zhou, Yan Zou, Yi-Ya Yang, Sha-Xi OuYang, Yu-Mei Liang

Open access · hybridAbstract read
In one paragraph

Article in Medical science monitor : international medical journal of experimental and clinical research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Kang-Han LiuDepartment of Nephrology, Hunan Provincial Peoples' Hospital, The First Affiliated Hospital of Hunan Normal University, Changsha, Hunan, China (mainland).
Nan ZhouDepartment of Nephrology, Hunan Provincial Peoples' Hospital, The First Affiliated Hospital of Hunan Normal University, Changsha, Hunan, China (mainland).
Yan ZouDepartment of Nephrology, Hunan Provincial Peoples' Hospital, The First Affiliated Hospital of Hunan Normal University, Changsha, Hunan, China (mainland).
Yi-Ya YangDepartment of Nephrology, Hunan Provincial Peoples' Hospital, The First Affiliated Hospital of Hunan Normal University, Changsha, Hunan, China (mainland).
Sha-Xi OuYangDepartment of Nephrology, Hunan Provincial Peoples' Hospital, The First Affiliated Hospital of Hunan Normal University, Changsha, Hunan, China (mainland).
Yu-Mei LiangDepartment of Nephrology, Hunan Provincial Peoples' Hospital, The First Affiliated Hospital of Hunan Normal University, Changsha, Hunan, China (mainland).
Hunan Normal University · CNHunan Provincial People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND Long-term exposure to hypertonic and high glucose in peritoneal dialysis fluid can result in peritoneal fibrosis. Spleen tyrosine kinase (SYK) has a role in inflammation and fibrosis. This study aimed to investigate the role of SYK in an in vivo rat model of peritoneal fibrosis and in rat peritoneal mesothelial cells (PMCs) in vitro and to investigate the underlying mechanisms. MATERIAL AND METHODS Sprague-Dawley rats (N=24) were randomized into the sham control group (N=6); the peritoneal fibrosis group (N=6) treated with intraperitoneal chlorhexidine digluconate; the SYK inhibitor group (N=6), treated with chlorhexidine digluconate and fostamatinib; and the TGF-ß inhibitor group (N=6), treated with chlorhexidine digluconate and LY2109761. The rat model underwent daily intraperitoneal injection with 0.5 ml of 0.1% chlorhexidine digluconate. Rat peritoneal mesothelial cells (PMCs) were cultured in vitro in high glucose. SYK expression was measured by quantitative reverse transcription-polymerase chain reaction (qRT-PCR) and Western blot. Enzyme-linked immunosorbent assay (ELISA) and qRT-PCR measured inflammatory mediators. Transforming growth factor-ß1 (TGF-ß1) and Smad3 were detected by Western blot. Short hairpin RNA (shRNA) was used to target the SYK gene. RESULTS SYK was upregulated in the rat model of peritoneal fibrosis and was induced rat PMCs cultured in high glucose. Knockdown of SYK and inhibition of TGF-ß1 significantly reduced fibrosis and inflammation. Findings in the in vivo rat model confirmed that SYK mediated peritoneal fibrosis by regulating TGF-ß1/Smad3 signaling. CONCLUSIONS In a rat model and in rat PMCs, expression of SYK increased peritoneal fibrosis through activation of the TGF-ß1/Smad3 signaling pathway.

Indexed as

AnimalsChinaChlorhexidineDisease Models, AnimalDisease ProgressionPeritoneal DialysisPeritoneal FibrosisPeritoneumRatsRats, Sprague-DawleySignal TransductionSmad3 ProteinSyk KinaseTransforming Growth Factor beta1Chlorhexidinechlorhexidine gluconateSmad3 ProteinSmad3 protein, ratSyk KinaseSyk protein, ratTransforming Growth Factor beta1

Identifiers

PMID31812978
PMCPMC6918804
OpenAlexW2992338715

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.